Market Overview

X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta® (axitinib) in Patients with Clear Cell Renal Cell Carcinoma

Share:

Study designed to evaluate X4P-001-IO in combination therapy to be
presented at the Annual Meeting of the Association Society of Clinical
Oncology

X4
Pharmaceuticals
, a clinical stage biotechnology company developing
novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat
cancer and rare disease, today announced that an abstract highlighting X4P-001-IO,
the company's CXCR4 antagonist, has been selected for poster
presentation at the 2018 Association Society of Clinical Oncology (ASCO)
annual meeting, taking place June 1-5 in Chicago. The presentation will
describe clinical results from the Phase 2 expansion of an ongoing Phase
1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in
patients with clear cell renal cell carcinoma (ccRCC).

Details of the presentation on X4P-001 are as follows:

Title:

    A phase 1/2 study evaluating the efficacy and safety of the oral
CXCR4 inhibitor X4P-001 in combination with axitinib in patients
with advanced renal cell carcinoma
 

Authors:

Ulka Vaishampayan, M.D., Barbara Ann Karmanos Cancer Institute,
Detroit, MI
Michael Atkins, M.D., Georgetown-Lombardi Comprehensive Cancer
Center, Washington, DC
 

Abstract #:

4510
 

Poster Session:

Genitourinary (Nonprostate) Cancer
 

Session Type:

Poster Discussion Session, chosen as a select poster where expert
discussants will highlight the most clinically applicable and
novel posters, with abstract authors participating as panel members

 

Date and Time:

June 2, 2018, 1:15 PM-2:30 p.m. CT

About X4P-001-IO in Cancer

X4P-001-IO
is an investigational selective, oral, small molecule antagonist of
C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in
abundance on certain immune cells and cancer cells and it plays a
critical role in immune cell trafficking, infiltration and activation in
the tumor microenvironment. CXCR4 signaling is disrupted in a broad
range of cancers, facilitating tumor growth by allowing cancer cells to
evade immune detection and creating a pro-tumor microenvironment.
X4P-001-IO has the ability to help restore immunity within the tumor
microenvironment and has the potential to enhance the anti-tumor
activity of approved and emerging oncology agents, such as checkpoint
inhibitors and targeted therapies. X4P-001-IO is being investigated in
several clinical studies in solid tumors.

About X4 Pharmaceuticals

X4
Pharmaceuticals
is developing novel therapeutics designed to improve
immune cell trafficking to treat cancer and rare diseases. The Company's
oral small molecule drug candidates antagonize the CXCR4
pathway, which plays a central role in immune surveillance. X4's most
advanced product candidate, X4P-001-RD, is in a Phase 2/3 study in
patients with WHIM syndrome, a rare genetic, primary immunodeficiency
disease. X4P-001-IO is currently under investigation in multiple
clinical studies in solid tumors. X4 was founded and is led by a team
with deep product development and commercialization expertise, including
several former members of the Genzyme leadership team, and is located in
Cambridge, MA. For more information, visit www.x4pharma.com.

Inlyta® is a registered trademark of Pfizer.

View Comments and Join the Discussion!